We are live on
!
Find out more
Marshall Wace North America Portfolio holdings
AUM
$23.5B
Turnover
51.87%
1-Year Est. Return
46.46%
This Fund
S&P 500
This Quarter
Est. Return
+7.23%
1 Year Est. Return
+46.46%
3 Year Est. Return
+108.51%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$17.7B
AUM Growth
-$2.27B
(-11%)
Cap. Flow
-$3.12B
Cap. Flow
% of AUM
-17.63%
Top 10 Holdings %
Top 10 Hldgs %
15.77%
Holding
1,947
New
557
Increased
335
Reduced
444
Closed
606
Avg Time Held Equity + Options
0.5
years
Top 10 Avg Time Held Equity + Options
0.6
years
Top 20 Avg Time Held Equity + Options
0.5
years
Avg Time Held Equity only
0.5
years
Top 10 Avg Time Held Equity only
0.6
years
Top 20 Avg Time Held Equity only
0.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$113M |
| 2 |
Berry Global Group, Inc.
BERY
|
+$106M |
| 3 |
Merck
MRK
|
+$95.9M |
| 4 |
Baidu
BIDU
|
+$85.8M |
| 5 |
IQVIA
IQV
|
+$83.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$229M |
| 2 |
Las Vegas Sands
LVS
|
+$150M |
| 3 |
Alibaba
BABA
|
+$131M |
| 4 |
Citigroup
C
|
+$130M |
| 5 |
Micron Technology
MU
|
+$105M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.57% |
| 2 | Technology | 15.56% |
| 3 | Consumer Discretionary | 13.38% |
| 4 | Industrials | 10.54% |
| 5 | Financials | 9.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Microsoft
MSFT
$4.01T
| $500M | 2.83% |
5,075,375
-366,326
| -7% | -$35.5M |
2017 Q1
5 quarters
|
|
2
Boston Scientific
BSX
$64B
| $293M | 1.65% |
8,948,629
-2,567,644
| -22% | -$77.4M |
2017 Q1
5 quarters
|
|
3
Quest Diagnostics
DGX
$26.4B
| $292M | 1.65% |
2,658,130
+214,446
| +9% | +$22.3M |
2017 Q1
5 quarters
|
|
4
Meta Platforms (Facebook)
META
$1.88T
| $272M | 1.54% |
1,401,223
-497,765
| -26% | -$89.9M |
2013 Q3
19 quarters
|
|
5
Zoetis
ZTS
$32.4B
| $270M | 1.52% |
3,168,080
+58,549
| +2% | +$4.94M |
2013 Q2
20 quarters
|
|
6
S&P Global
SPGI
$125B
| $266M | 1.5% |
1,305,895
-348,506
| -21% | -$68.8M |
2017 Q1
5 quarters
|
|
7
UnitedHealth
UNH
$365B
| $241M | 1.36% |
983,254
+126,006
| +15% | +$30.3M |
2017 Q1
5 quarters
|
|
|
8
Vertex Pharmaceuticals
VRTX
$129B
| $236M | 1.33% |
1,387,800
+727,532
| +110% | +$113M |
2017 Q1
5 quarters
|
|
9
DELISTED
Sealed Air
SEE
| $226M | 1.28% |
5,334,072
+1,074,609
| +25% | +$47.2M |
2017 Q1
5 quarters
|
|
|
ABMD
10
DELISTED
Abiomed Inc
ABMD
| $195M | 1.1% |
475,505
-61,737
| -11% | -$22.4M |
2017 Q1
5 quarters
|
|
11
CoStar Group
CSGP
$13B
| $194M | 1.1% |
4,708,210
-412,160
| -8% | -$15.9M |
2017 Q1
5 quarters
|
|
12
Carlisle Companies
CSL
$13.3B
| $189M | 1.07% |
1,743,816
+561,234
| +47% | +$59.4M |
2017 Q1
5 quarters
|
|
13
Agilent Technologies
A
$49.5B
| $183M | 1.04% |
2,965,320
-77,107
| -3% | -$5.03M |
2013 Q2
20 quarters
|
|
|
14
DELISTED
Berry Global Group, Inc.
BERY
| $174M | 0.98% |
4,127,186
+2,285,273
| +124% | +$106M |
2013 Q4
18 quarters
|
|
15
Global Payments
GPN
$22.3B
| $168M | 0.95% |
1,506,607
+463,060
| +44% | +$52.3M |
2017 Q2
4 quarters
|
|
16
Pfizer
PFE
$168B
| $157M | 0.88% |
4,550,201
-234,843
| -5% | -$8.03M |
2013 Q2
20 quarters
|
|
17
PTC
PTC
$21B
| $154M | 0.87% |
1,646,772
-200,604
| -11% | -$17.3M |
2017 Q1
5 quarters
|
|
18
Cboe Global Markets
CBOE
$32.2B
| $152M | 0.86% |
1,463,354
+214,432
| +17% | +$22.7M |
2018 Q1
1 quarter
|
|
19
DELISTED
Electronic Arts
EA
| $141M | 0.79% |
997,308
+31,341
| +3% | +$4.07M |
2017 Q2
4 quarters
|
|
20
US Foods
USFD
$22B
| $131M | 0.74% |
3,462,342
+157,570
| +5% | +$5.58M |
2017 Q4
2 quarters
|
|
21
Danaher
DHR
$163B
| $130M | 0.73% |
1,484,451
+110,101
| +8% | +$9.81M |
2013 Q4
18 quarters
|
|
22
Atmos Energy
ATO
$27.7B
| $128M | 0.72% |
1,417,083
+225,465
| +19% | +$19.5M |
2017 Q1
5 quarters
|
|
23
McDonald's
MCD
$172B
| $127M | 0.72% |
812,402
-109,541
| -12% | -$17.8M |
2013 Q3
19 quarters
|
|
|
ALXN
24
DELISTED
Alexion Pharmaceuticals
ALXN
| $125M | 0.7% |
1,005,169
-79,722
| -7% | -$9.32M |
2013 Q4
18 quarters
|
|
25
Teleflex
TFX
$5.43B
| $122M | 0.69% |
456,107
+129,455
| +40% | +$34.7M |
2017 Q1
5 quarters
|
|
Similar funds
NAM
Marshall Wace North America's Q2 2018 Portfolio in Review
As of Q2 2018, Marshall Wace North America held 1,947 positions worth $17.7B, down 11% from $20B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Marshall Wace North America withdrew a net $3.12B in Q2 2018, closing 606 positions and reducing 444 holdings. Its most notable exit was Time Warner Inc, an estimated $63.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 26% of assets, up from 22% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Marshall Wace North America opened a new position in IQVIA worth $83.1M.
- Marshall Wace North America's largest Q2 2018 buy was IQVIA: 832,159 shares worth $83.1M.
- Marshall Wace North America added most to Vertex Pharmaceuticals in Q2 2018, an estimated $113M increase.
- Marshall Wace North America's biggest Q2 2018 reduction was Johnson & Johnson, cutting an estimated $229M.
- Marshall Wace North America fully exited Time Warner Inc in Q2 2018, selling an estimated $63.3M.
- Marshall Wace North America's ten largest holdings make up 16% of its $17.7B portfolio in Q2 2018.
- Marshall Wace North America opened 557 new positions and closed 606 in Q2 2018.
- Marshall Wace North America's portfolio value fell 11% quarter-over-quarter to $17.7B.
Based on Marshall Wace North America's 13F filing for Q2 2018, filed 14 Aug 2018.